Yükleniyor... / Loading...
This study uses metabolomic methods to examine dysregulated lipid (fat) metabolism, through blood samples, in patients with CMT2A (Charcot-Marie-Tooth type 2A) caused by mutations in the MFN2 gene. It enrolled adult patients with clinically and electrophysiologically confirmed CMT2A who carry an MFN2 mutation, along with age- and sex-matched control subjects. It was a non-phased study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: For all participants : * Adult person * Person on an empty stomach at the time of inclusion * Person who signed the study participation consent form * Person affiliated or beneficiary of a social security scheme Patients Charcot-Marie-Tooth : * Patient with symptoms of Charcot-Marie-Tooth disease on clinical examination clinical examination * Patient with axonal neuropathy confirmed by an electrophysiological study electrophysiological study with a median nerve conduction velocity \> 38 m / s * Patient with documented pathogenic mutation (class 4 or class 5) in the MFN2 or patient with a variant of uncertain significance, as determined by the laboratory performing the test, if the variant of unknown significance has been found in found in multiple affected individuals in a family and not found in unaffected family members in unaffected family members. Control subject : * Each control is matched in age and sex to a case previously included in the study. Exclusion Criteria: For all participants : * Pregnant, breastfeeding or parturient woman * Person deprived of liberty by judicial or administrative decision * Person subject to forced psychiatric care * Person subject to a legal protection measure * Person unable to give consent Patients Charcot-Marie-Tooth : * Patient with a neuropathy other than CMT2A (such as diabetic neuropathy or any other cause of acquired neuropathy) neuropathy or any other cause of acquired neuropathy), medical history of kidney stones kidney stones or cardiovascular risk factors (dyslipidaemia diabetes, severe obesity (BMI \>35 kg/m²)) * Patient treated with Idebenone at the time of inclusion. (It is possible to include a patient treated with Idebenone if the treatment was interrupted at least 5 days before) Control subject : * Person with neuropathy, medical history of kidney stones or cardiovascular risk factors cardiovascular risk factors (dyslipidaemia, diabetes, severe obesity (BMI \>35 kg/m²))